Shares of Kodiak Sciences Inc. (KOD) hit a new high of $16.30 during intraday trading yesterday, driven by momentum around its three late-stage drug candidates, which are designed to overcome major shortcomings of current treatments for a wide range of retinal diseases.
The company's pipeline includes Tarcocimab, KSI-501, and KSI-101.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com